Literature DB >> 9885232

The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils.

H Petering1, O Götze, D Kimmig, R Smolarski, A Kapp, J Elsner.   

Abstract

Chemokines play an important role in attracting granulocytes into sites of inflammation. Two chemokine subfamilies differ in their biologic activity for different granulocyte subsets. Whereas CXC chemokines such as interleukin-8 (IL-8) activate predominantly neutrophils, CC chemokines such as RANTES and eotaxin activate predominantly eosinophils. However, controversial results have been published in the past regarding the biologic role of IL-8 in eosinophil activation, particularly in allergic diseases. In this study, we investigated the functional evidence and expression of both IL-8 receptors, CXCR1 and CXCR2, on highly purified human eosinophils. In the first set of experiments, a chemotaxis assay was performed showing that IL-8 did not induce chemotaxis of eosinophils. In addition, and in contrast to neutrophils and lymphocytes, IL-8 did not induce a rapid and transient release of cytosolic free Ca2+ ([Ca2+]i) in eosinophils, even after preincubation with TH1- and TH2-like cytokines. To investigate whether neutrophil contamination might be responsible for the reported IL-8 effects on eosinophils, neutrophils were added to highly purified eosinophils from the same donor in different concentrations. Interestingly, as little as 5% of neutrophil contamination was sufficient to induce an increase of [Ca2+]i after stimulation with IL-8. Flow cytometry experiments with monoclonal antibodies against both IL-8 receptors demonstrated no expression of CXCR1 and CXCR2 on eosinophils before or after cytokine activation. Reverse transcriptase-polymerase chain reaction experiments showed that eosinophils, in contrast to neutrophils and lymphocytes, did not express mRNA for CXCR1 and CXCR2. In summary, this study clearly demonstrates that CXCR1 and CXCR2 are not expressed on human eosinophils, even after priming with different bioactive cytokines. Because the CXC chemokine IL-8 did not induce in vitro effects on human eosinophils, IL-8 may also not contribute in vivo to the influx of eosinophil granulocytes into sites of allergic inflammation. Our results suggest that CC chemokines such as eotaxin, eotaxin-2, and MCP-4 are predominant for the activation of eosinophils.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9885232

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.

Authors:  Gong Yang; Daniel G Rosen; Guangzhi Liu; Fan Yang; Xiaoqing Guo; Xue Xiao; Fengxia Xue; Imelda Mercado-Uribe; Jiaoti Huang; Sue-Hwa Lin; Gordon B Mills; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

Review 2.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

3.  Diesel exhaust particulates exacerbate asthma-like inflammation by increasing CXC chemokines.

Authors:  Jiyoun Kim; Sudha Natarajan; Louis J Vaickus; Jacqueline C Bouchard; Dominic Beal; William W Cruikshank; Daniel G Remick
Journal:  Am J Pathol       Date:  2011-10-01       Impact factor: 4.307

4.  Ascaris suum-derived products induce human neutrophil activation via a G protein-coupled receptor that interacts with the interleukin-8 receptor pathway.

Authors:  F H Falcone; A G Rossi; R Sharkey; A P Brown; D I Pritchard; R M Maizels
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  CXCL6 (granulocyte chemotactic protein-2): a novel chemokine involved in the innate immune response of the amniotic cavity.

Authors:  Pooja Mittal; Roberto Romero; Juan Pedro Kusanovic; Samuel S Edwin; Francesca Gotsch; Shali Mazaki-Tovi; Jimmy Espinoza; Offer Erez; Chia-Ling Nhan-Chang; Nandor G Than; Edi Vaisbuch; Sonia S Hassan
Journal:  Am J Reprod Immunol       Date:  2008-09       Impact factor: 3.886

6.  Highly up-regulated CXCR3 expression on eosinophils in mice infected with Schistosoma japonicum.

Authors:  He Li; Hu Chunsong; Cai Guobin; Zhang Qiuping; Li Qun; Zhang Xiaolian; Huang Baojun; Zhang Linjie; Liu Junyan; Jiang Mingshen; Tan Jinquan
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 7.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

8.  Giardia duodenalis cathepsin B proteases degrade intestinal epithelial interleukin-8 and attenuate interleukin-8-induced neutrophil chemotaxis.

Authors:  James A Cotton; Amol Bhargava; Jose G Ferraz; Robin M Yates; Paul L Beck; Andre G Buret
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

9.  Fibroblast activation protein α-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation.

Authors:  Zhang Wen; Qiaofei Liu; Jihua Wu; Banghao Xu; Jilong Wang; Lizhou Liang; Ya Guo; Minhao Peng; Yupei Zhao; Quan Liao
Journal:  Ann Transl Med       Date:  2019-10

10.  Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment.

Authors:  Antonio Brú; Juan-Carlos Souto; Sonia Alcolea; Rosa Antón; Angel Remacha; Mercedes Camacho; Marta Soler; Isabel Brú; Amelia Porres; Luis Vila
Journal:  Mediators Inflamm       Date:  2010-02-11       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.